

S 1367

United States Pharmaceutical Supply Chain Review Act

Congress: 117 (2021–2023, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Apr 26, 2021

Current Status: Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.

Latest Action: Read twice and referred to the Committee on Banking, Housing, and Urban Affairs. (Apr 26, 2021)

Official Text: <https://www.congress.gov/bill/117th-congress/senate-bill/1367>

Sponsor

Name: Sen. Warren, Elizabeth [D-MA]

Party: Democratic • **State:** MA • **Chamber:** Senate

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Rubio, Marco [R-FL]	R · FL		Apr 26, 2021

Committee Activity

Committee	Chamber	Activity	Date
Banking, Housing, and Urban Affairs Committee	Senate	Referred To	Apr 26, 2021

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 S 1366	Related bill	Apr 26, 2021: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary (as of Apr 26, 2021)

United States Pharmaceutical Supply Chain Review Act

This bill requires the Federal Trade Commission to submit annually to Congress a report on foreign investment in the U.S. pharmaceutical industry. The report shall address, among other topics, the effect of the industry's reliance on foreign manufacturing.

Actions Timeline

- **Apr 26, 2021:** Introduced in Senate
- **Apr 26, 2021:** Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.